Pfizer Diflucan switch for vaginal yeast infections proposed in U.K..
This article was originally published in The Tan Sheet
Executive Summary
DIFLUCAN SWITCH TO NONPRESCRIPTION STATUS IN U.K. PROPOSED by the Medicines Control Agency for the one-day treatment of vaginal yeast infec-tions. Pfizer received prescription approval for the use of a one-day treatment regimen with Diflucan (fluconazole) in the U.S. last summer ("The Tan Sheet" July 11, 1994, p. 8).
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning